Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer

J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1797-8. doi: 10.1097/01.JTO.0000407562.07029.52.
No abstract available

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / metabolism
  • Clinical Trials as Topic
  • Ephrins / antagonists & inhibitors*
  • Ephrins / metabolism
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / metabolism
  • Proto-Oncogene Proteins / antagonists & inhibitors*
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins c-met / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-met / metabolism
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Receptor Protein-Tyrosine Kinases / metabolism
  • Receptor, Fibroblast Growth Factor, Type 1 / antagonists & inhibitors*
  • Receptor, Fibroblast Growth Factor, Type 1 / metabolism
  • Receptor, Platelet-Derived Growth Factor alpha / antagonists & inhibitors*
  • Receptor, Platelet-Derived Growth Factor alpha / metabolism
  • c-Mer Tyrosine Kinase

Substances

  • Antineoplastic Agents
  • Ephrins
  • Proto-Oncogene Proteins
  • FGFR1 protein, human
  • MERTK protein, human
  • MET protein, human
  • Proto-Oncogene Proteins c-met
  • Receptor Protein-Tyrosine Kinases
  • Receptor, Fibroblast Growth Factor, Type 1
  • Receptor, Platelet-Derived Growth Factor alpha
  • c-Mer Tyrosine Kinase